Arecor Therapeutics plc
(“Arecor” or the “Group”)
US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES
- Endorses potential of proprietary Arestat™ platform technology to invent novel, enhanced therapeutics in $210 billion monoclonal antibody market
- Further strengthens Group’s extensive patent portfolio
Cambridge, UK, 26 April 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11608357) protecting a novel formulation platform that enables the development of enhanced monoclonal antibodies.
Monoclonal antibodies represent a key segment of the biopharmaceuticals market, valued at $210 billion in 2022 and are projected to see a compound annual growth rate (CAGR) of 11.04% from 2023 to 20301.
There has been a strong drive towards patient-centricity in the biopharmaceutical industry, particularly in the development of convenient dosage forms. However, achieving such desirable dosage forms is often hampered by insufficient stability or high viscosity of monoclonal antibodies when formulated using conventional formulation approaches. To address this problem Arecor has developed a number of highly innovative, proprietary formulation platforms enabling superior stability of monoclonal antibodies under various stress conditions. This US patent protects one of these proprietary formulation platforms within the Group’s broader Arestat™ technology.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: “Whilst a number of novel therapeutic modalities are being developed, such as complex engineered protein constructs or mRNA therapies, monoclonal antibodies continue to dominate the biopharmaceutical field. Safety and efficacy are obviously the key criteria for any new product, but the increasing focus on patient-centricity and improved convenience of delivery often requires superior product stability which is often difficult to achieve using conventional approaches. Our highly innovative formulation technology addresses these challenges and, when applied, we are able to develop enhanced novel pharmaceutical products, both for our growing partnerships with Pharma companies and in our proprietary pipeline. This US patent is a very important addition to our IP portfolio, protecting a formulation design space that enables monoclonal antibodies with superior stability.”
Arecor leverages its Arestat™ technology in partnerships with leading pharmaceutical and biotechnology companies to deliver enhanced products under a technology licensing model, as well as developing an internal portfolio of proprietary products in diabetes and other indications. As part of this strategy Arecor continues to invest in a strong patent portfolio to protect the Arestat™ platform, currently comprising 38 patent families and >75 granted patents.
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700